INTRODUCTION
Knowledge that the Human Immunodeficiency Virus (HIV) targets and incapacitates the immune system, our primary defense against disease, compelled efforts to find a way to manage the pathogen. Today, 30 years after the identification of HIV, medications have made infection by HIV a chronic manageable disease in the United States; however, there remains no cure. By the end of 2010, the World Health Organization stated that there were 34 million people infected with HIV worldwide; that year alone, 2.7 million people became newly infected, and 1.8 million died from HIV-related diseases.
HIV infection reduces the presence of an important immune modulator, a glycoprotein called the CD4 helper cell. CD4 helper cells are necessary in the initiation of a competent immune response when any potentially lethal matter invades the body. CD4 cells are necessary to amplify the T-cell's ability to coordinate the entire immune system's response. After combining with CD4 cells, the T-cells are then able to carry out a variety of the primary functions of the immune system. Some T-cells are involved in the production of antibodies; others identify, surround, destroy, and eliminate invading pathogens including HIV and other common infections. Thus, infection by HIV decreases the absolute number of CD4 helper cells available, which effectively downregulates the ability of the immune system to fight disease. The absolute CD4 count is part of the routine blood work of HIV infected patients and is used as a measure of immune health as well as a primary factor in determining a patient's prognosis for survival (A. H. Miller, 2010; Turner, Markson, & Taroni, 1996) .
The knowledge that the HIV virus first infects, then disables, and ultimately destroys key elements of the human immune system leaving its host unable to fight opportunistic infections quickly focused scientific efforts to understand and control the spread of this pathogen (Cohen, 1993) . Fear of the contagion made funding available to research any intervention that offered hope for the containment of the virus. This facilitated a willingness to investigate complementary and alternative therapies to improve the capacity of the immune system and to treat the symptoms of infection (Duggan, Peterson, Schutz, Khuder, & Charkraborty, 2001) .
Concomitantly with the investment of resources to determine a medical solution to HIV in the early 1980s, scientists were investigating a myriad of related phenomenon, and some important theories were converging. For example, Piaget, who was studying stages of cognitive development in children, and Darwin, who studied evolution, described inherently greater plasticity in humans, both in our genetic heritage and in an individual's potential during development. This caused a minor paradigm shift away from the 16th-century mind-body dualistic tradition upon which Western medicine had evolved. Scientists began taking a broader, more systems view of adaptation via assimilation and accommodation. With regard to developments in neuroscience, the capacity of the brain to change in response to experience was emerging as critical feature of brain development honed by natural selection. The awareness that the brain is dynamically impacted by both exogenous and endogenous events led to studies proving that stress was a factor modulating immunological health (Sommershof et al., 2009) . By the late 1980s, physicians and mental health clinicians considered their patient's emotional state to be a major cofactor in the health of their patients.
The central nervous system (CNS) affects immunity through extensive bidirectional neuronal and neuroendocrine connections (Besedofsky et al., 1983; Black, 1994; Darjik & Berkenbosch, 1991; Felten & Felten, 1991) . Although research shows that brain dysregulation occurs early after HIV infection (Baldeweg et al., 1997) , studies also demonstrate that the CNS can be conditioned to suppress (Bvobjerg, Redd, Maier, & Hollard 1990; Klosterhalfen & Klosterhalfen, 1983) or enhance (Solvason, Ghanta, & Hiramoto, 1988) elements of immune function. Because emotions modulate the production of neuropeptides and neurotransmitters, they also influence the immune system's response to invading pathogens. Although some investigators found that relaxation improved mood, these studies failed show a positive correlation with CD4 count in HIVþ subjects (Aurbach, Oleson, & Sloman, 1992; Lutgendorf et al., 1997) . Other studies, however, have shown consistently positive correlations between the suppression of immune function and a depressed mood (V. Miller et al., 1999) . In one study, CD4þ T lymphocytes increased in individuals who enrolled in stress reduction programs (Creswell, Myers, Cole, & Irwin, 2009) . As a result, we chose to include measures from the Symptom Checklist (SCL-90) and a stress inventory form in the current study to track correlations between emotional states and changes in CD4 counts.
Biofeedback training has a positive impact on a variety of symptoms not previously thought to be controllable (Andreychuk & Shriver, 1975) . The physiological signal utilized by neurofeedback is the electroencephalogram (EEG), which is shaped by the feedback to guide it toward better functioning. The EEG reflects the summed rhythmic discharges from projections of thalamic nuclei (Striade, McCormick, & Sejnowski, 1993) and has utility as an indicator of normal states of consciousness as well as identifying localized and generalized brain pathology. Studies dating back to 1969 indicate that the frequency and topography of human EEG respond to operant conditioning by neurofeedback training, which alters the incidence, magnitude, and organization of neuronal oscillations (De Pascalis & Silveri, 1986; Sterman, 1996) . Neurofeedback training is an accepted intervention, demonstrating efficacy with regard to treating certain disorders by improving CNS function (Tozzo, Elfner, & May, 1988) .
The effects of neurofeedback on the immune system have been investigated from both a theoretical and experimental standpoint (Auerbach et al., 1992; Schummer, 1996) . Auerbach et al. studied the effects of thermal biofeedback on a group of HIVþsubjects and found the group showed improvement in a variety of symptoms, but there was no report of changes in CD4 count. Because neurofeedback training impacts brain function at the neuronal level, it has been hypothesized that neurofeedback training would directly modulate the extensive bidirectional neuronal connections and feedback loops in and between the CNS and immune system (Schummer, 1996) . Because there is an extensive body of evidence showing that alpha or alpha-theta neurofeedback training enhances mood, it is reasonable to suggest there might be an increase in CD4 count in subjects undergoing this particular treatment. As the amplitude in the alpha (8-12 Hz) and theta (4-8 Hz) frequency bands increase in the human EEG, a subject reports less tension, lower levels of anxiety, and occasional drowsiness. Thus, alpha and theta were the frequencies chosen for the neurofeedback protocol in the present study.
Cranial electrical stimulation (CES) is another alternative treatment that is often compared to neurofeedback training. CES protocols use a small, pulsed electric current across the head every day for about 15 to 30 min. Those who manufacture and use this treatment claim they experience benefits such as lowered stress levels and improved sleep. Others claim it decreased symptoms associated with anxiety and depression. Although its use remains experimental, we chose to include this as a treatment condition to see what effects CES may have on our dependent variables.
For the present study, we predicted neurofeedback and cranial electrotherapy would significantly reduce HIV-related symptoms compared to the control group. In addition, we hypothesized that neurofeedback and cranial electrotherapy would significantly reduce subjective measures of stress compared to the control group. We also predicted an increase of CD4þ cell counts in HIV-infected individuals compared to the control group with neurofeedback and cranial electrotherapy.
METHODS

Subjects
HIVþ volunteers without overt AIDS were recruited from the community (Hollywood, CA). Selection criteria were set as 18 to 55 years of age with a total of total CD4þ counts from 150 to 650=cc (lab normal 400 to 1,770). All subjects were interviewed to ensure qualifications for the study. Subjects with overt depression or other Axis I diagnoses and those using illicit drugs or alcohol were excluded from the study. The study was privately funded and was not reviewed by an Institutional Review Board. Volunteers did, however, complete informed consent forms prior to their participation.
Procedure
After informed consent was obtained, participants were given the Symptom Checklist (SCL-90-R, Version 1.0, 1990 revision, Derogatis) to fill out every week of study. The checklist scored symptoms such as fever, fatigue, pain, nausea, and insomnia. At initiation and at 2 and 4 months, complete blood counts including total lymphocyte count and serum chemistry were measured. Concomitantly, absolute CD4þ and CD8þ counts were measured as previously described (Flaherty, Wagner, Gross, & Panyik, 1997 ; Consolidated Lab Services, Van Nuys, CA) on samples collected during morning attendance at the clinic. CD4þ and CD8þ cells were counted on blood (50 mL) incubated for 15 min at room temperature in the dark with 20 mL color-tagged monoclonal antibodies (Becton Dickinson, San Jose, CA). Red blood cells were lysed, and remnant cells were washed and assayed by a fluorescence-activated cell sorter (Becton Dickinson True Count Method).
Patients were randomly divided into four groups (n ¼ 10=group): (a) in office, EEG alpha neurofeedback; (b) at home daily cranial electrotherapy; (c) both in office neurofeedback and home electrotherapy; and (d) waitlist control. Participants in the neurofeedback treatment condition were given neurofeedback therapy for 20 min twice weekly for 16 weeks under the guidance of a randomly selected investigator who continued with that subject throughout training. Individuals in the cranial electrotherapy group were trained to use the product and asked to train at home every day for 20 min. The combined therapy group was given the EEG neurofeedback training for the same weekly time (twice=week) as well as daily cranial electrotherapy.
Subjects in the waitlist control group were interviewed weekly and continued with usual therapy with no other intervention. All subjects continued on their usual medical therapies and were not informed of any results until completion of the study. A one-way analysis of variance was used to test for overall difference among groups for each dependent variable. This was followed by pairwise comparisons between groups using a (post hoc) Dunnett's t test.
EEG Biofeedback Treatment Protocol
EEG neurofeedback was performed using linked ears (reference and ground) with the active electrode at Oz (occipital midline according to the International 10-20 system, Cap Scan, New York, NY). Fast Fourier Transform using a Cooley-Tukey algorithm was applied to each 2.56-s epoch, and the square root of the absolute power coefficients was computed for each epoch. Subjects were rewarded by a tone when alpha amplitude (8-12 Hz) exceeded their initial testing amplitude (30 s with eyes closed). Drifting into sleep was actively prevented by constantly monitoring the EEG activity of subjects during neurofeedback. If EEG deteriorated into sleep, the assigned investigator would tell the subject to refocus on the tone. When subjects could sustain alpha amplitude at double the baseline level for 20 minutes, the reward tone was shifted to a slightly lower frequency (i.e., low alpha-theta, 6-8 Hz); training was continued for a total of 16 weeks. Training did not reward slower (i.e., theta, 4-6 Hz) frequencies, which instead of quiet attention indicate potential pathology or patterns of extreme drowsiness (Johnson, Seales, Naitoh, Church, & Sinclair, 1979) . To minimize placebo bias (Cott, Pavloski, & Goldman, 1981) , subjects were not informed of subjective or immune benefits they might derive from training.
Cranial Electrotherapy Treatment Protocol
Cranial electrotherapy was conducted using an electrical stimulating device (''electrotherapy'') believed by its proponents to induce alpha by application of oscillating 10 Hz, 200 mamp currents applied to both ears (Alpha-Stim Model 2000 GL, Hollywood, CA, Smith=Shiromoto; Brotman, 1989; Wilson & Childs, 1998) . The intensity of the electrical current did not allow verification of actual EEG amplitude changes caused by the applied signal.
RESULTS
At baseline, there were no group differences in CD4 cell count (p ¼ .72). All subjects completed the entire 16 weeks of study and the entire symptom questionnaire on each occasion by previously defined rules. All subjects who received EEG neurofeedback with or without electrotherapy could sustain criterion alpha amplitude for 20 min by completion of the study. The average time for transition from mid-alpha frequency to low alpha was 10 weeks with a range of 6 to 14 weeks. No subject demonstrated increased amplitude of delta frequencies. EEG significantly differed between subjects before and after neurofeedback training. Because results were intended to evaluate responses to particular treatments and not relevance to EEG changes, EEG measures were not performed in control subjects or those who received only electrotherapy. There is no a priori reason to have expected that alpha amplitude would change during the course of the study for control subjects, none of whom developed overt neurological signs during the study.
Subjects receiving EEG neurofeedback reported fewer symptoms (Table 1) , clearer mind, less physical pain, less subjective stress, and increased energy. The score on the Symptom Checklist decreased after neurofeedback alone and neurofeedback plus electrotherapy (see Table 1 ; p < .01) in comparison to the control groups. Results did not significantly differ from control subjects for those who received electrotherapy alone (p ¼ .29).
Baseline total CD4þ lymphocyte counts did not differ between groups (p ¼ .72). After 16 weeks, CD4þ counts were significantly higher in the neurofeedback (p < .02) and combined neurofeedback=electrotherapy (p < .05) groups (see Figure 1) . Changes in CD4þ counts were significant at 8 weeks for those who received EEG neurofeedback training plus electrotherapy (p < .01) and neurofeedback alone (p < .01). During EEG neurofeedback training, CD4þ levels significantly increased between Weeks 8 and 16 (p < .01), but no significant change occurred from Weeks 8 to 16 for subjects who received both neurofeedback training and electrotherapy (p ¼ .47). Similar results at 16 weeks were found for total CD4þ counts, for the ratio of CD4þ to CD8þ cells, and for CD4þ cells expressed as a percentage of total lymphocytes (Table 2) . No significant change occurred in total lymphocyte count. No significant change in CD4þ counts was noted after electrotherapy alone or control conditions at 8 and 16 weeks (p ¼ .5), but there was a significant increase from 8 to 16 weeks after electrotherapy alone (p < .05). Because there was no statistical difference between the neurofeedback and combined groups at the 2-and 4-month time points, we dismissed the possibility of an interaction between neurofeedback and cranial electrotherapy during combined therapy.
DISCUSSION
This study has shown that neurofeedback may be an effective tool in the treatment of CD4 counts. Furthermore, these effects were not seen in those subjects who received cranial electrotherapy, consistent with that fact that the neurofeedback and combined groups did not show significant differences. Patients with symptomatic HIV infection were able to train with alpha neurofeedback to enhance amplitude of alpha rhythms. This training improved symptoms of stress and illness, and absolute CD4þ counts were also increased. Symptoms were not improved in the waitlist control group. There was a significant increase of CD4þ counts within 2 months of electrotherapy and neurofeedback combined that persisted for the remaining 2 months of training. With neurofeedback alone, there was a nonsignificant trend to increased CD4þ counts after 2 months of training even though symptoms and stress had improved significantly within 2 months. By 4 months, the improvement of CD4þ counts reached statistical significance. The increased significance over time supports a true shift toward increased production of CD4þ cells and not merely demargination. Electrotherapy is reported to improve mood (Smith & Shiromoto, 1992) , improve attention (Brotman, 1989; Madden & Kirsche, 1987; Wilson & Childs, 1988) , and decrease fear responses by way of the limbic system (Dymond, Coger, & Serafetinides, 1975) . This method led to a time-wise trend to increase CD4þ counts, but results were not significantly higher than baseline after 16 weeks in the current studies. Stress inventory and symptom checklist scores tended to be lower 74  78  81  99  110  93  82  86  90  90  86  73  93  86  Alpha Stim  55  47  62  47  86  81  74  75  77  71  71  66  59  73  55  Neurofeedback  42  40  35  31  33  29  23  23  23  28  23  24  21  21  29  Combined  42  35  38  30  30  25  23  24  22  21  24  25  25  21  17 Note. Results are shown for the average scores received between groups on the SCL-90-R diagnostic questionnaire. This test, distributed by the Pearson Assessment and Information group, consists of 90 items that correlate with the measure of psychological distress in each subject. FIGURE 1. Average CD4þ T lymphocyte counts per cubic millimeter in each group at baseline, two months, and four months. Note. CD4 levels were measured via blood withdrawals in all subjects during major time points of the study. CD4þ T lymphocyte count is the primary indicator of HIV disease progression. (Color figure available online.) and CD4þ counts tended to be higher after electrotherapy, but this did not reach statistical significance. This supports the impact of neurofeedback compared to electrotherapy, which appears to have acted in the direction of improved symptoms and stress. In comparison, improvement of CD4þ counts was significant and was greater after neurofeedback. The mechanism(s) of immune benefits was not determined by the current study. One might have expected that neurofeedback training could decrease stress (Hardt & Kamiya, 1978) by promoting relaxation. This was not the usual response of subjects in the current study, many of whom instead reported greater energy and clarity of thoughts. In prior studies Note. This data tabulates raw data of CD4þ lymphocyte counts for each individual during the major time points of the experiment during which plasma was extracted and biochemically analyzed (baseline, 2 months, and 4 months). Subjects are named based on the group to which they are assigned: control (C), Alpha-Stim only (AS), neurofeedback only (N), or combined neurofeedback=Alpha-Stim (NAS). The absolute differences of the counts at each assessment point are also shown, as well as the percent change of these values over the 4-month period.
of therapies intended to decrease stress in HIV patients, symptoms improved, but CD4þ counts did not increase (Auerbach et al., 1992; Lutgendorf et al., 1997) . The current findings may stem from lower anxiety (Peniston & Kulkokosky, 1991) , but this would have been more likely in the most anxious subset (Hardt & Kamiya, 1978) , and such subjects were not studied. Electrotherapy is reported to decrease fear perception and depression, but no significant CD4þ benefits from such therapy were found in the current study. Depression is also reported to improve after alpha EEG training (Saxby & Peniston, 1995) , yet the exclusion of depressed subjects minimized most effects of this variable in the study. Higher CD4þ counts may have resulted from episodes of rest during neurofeedback, but rest alone for as long as 60 min was reported to decrease CD4þ counts (Campbell, Aurelius, Blowes, & Harvey, 1997) . So it appears that relaxed mood alone does not explain the benefits observed in the present study. One distinction between relaxation training and EEG neurofeedback is the ongoing (real-time) validation during training by rigorous neurophysiologic criteria. It is not clear whether this element led to greater psychoimmunological responses.
The benefits in the current study may have derived from attention given with verbal instructions from the trainer (Watson & Herder, 1980) , but such benefit was not shown in previous studies (Auerbach et al., 1992; Lutgendorf et al., 1997; McCain, Zeller, Cella, Urbanski, & Novak, 1996) . It cannot be definitively confirmed that such attention did not lead to these results, but the attention from other measures has not led to such effects. A true ''active'' control measure that mimicked the attention devoted to applying the neurofeedback apparatus might have supported the lack of impact from such investigator attention, but such an experimental mode was not performed in the current studies. Subject prejudice may have caused these experimental differences, but others have shown that expectations and hopes did not differ between HIV patients using conventional and alternative psychotherapy including meditation (Langewitz, Ruttimann, Laifer, Maurer, & Kiss, 1994) . Hardiness was reported to be greater in those who sought such alternative therapies (Carson, 1993) . This was not likely to have been a factor in the current studies based on the randomized design. Lack of baseline differences between study groups supports absence of selection bias.
It appears that factors such as relief of anxiety, lowered stress, improved depression, and rest or relaxation alone do not explain the benefits found in the current studies. One subject obtained a home device and continued EEG alpha training after completion of study and was able to normalize CD4þ levels (1,400=cc) with no change of antiviral therapy; 2 years later she became asymptomatic and was able to return to full-time work. Although prior publications have not shown the same immune benefits as the current studies, there may be other EEG approaches not yet tested to achieve the same end, including increased coherence (Dillbeck & Vesely, 1986) and enhanced fast frequency sensorimotor rhythms.
EEG changes derive from the dynamics of thalamic relay cell polarization that impact intrinsic oscillation within thalamocortical relay circuits (Striade et al., 1993) . Lesion experiments and depot injection studies support localized CNS effects leading to increased alpha power (Schellenburg, Schwarz, Knorr, & Haute, 1992) . The protocol used most often in clinical practice, and in the current studies, applies symbolic reinforcement to enhance particular rhythms. There might have been modification in the chain of neuroimmunologic control, but such changes have yet to be verified after neurotherapy.
It is not known how alpha EEG neurofeedback led to improved immune function. Similar shifts in subjective mood can be obtained with either increased or decreased alpha activity (Cott et al., 1981) . There may be a threshold for benefit attained by increasing amplitude of low-frequency activity. Such a pattern of enhanced alpha activity may be found in some normal subjects (De Prado, Da Silva, & Lima, 1993) and among regular practitioners of meditation (Delmonte, 1984) , but such treatments have not led to the same benefits as occurred in HIVþ patients after neurofeedback. Lowamplitude activity may indicate brain atrophy (Harden, Daras, Tuchman, & Koppel, 1993) , but there were no indications of such diminished alpha amplitude or of organic psychosis in the patients during the current studies. Similarly, markedly high amplitude of slow frequency components, which would have reflected local brain pathology, was not evident. Selective enhancement of alpha amplitude, as in the current studies, related to improved mood, vigor, and immune function.
The neurochemical distinctions were not investigated. Incoming peptidergic signals may be changed with EEG training through altered endopeptidase activity (Fricchoine & Stefano, 1994) and neurotransmitter alternations (Moldofsky, 1989) . EEG neurofeedback may cause dendritic sprouting and shift neural programming (Diamond, Johnson, & Ingham, 1975; Scheibel, Conrad, Perdue, Tomiyasu, & Wechsler, 1991; Sterman, 1996) , and it is possible that this contributed to immune changes.
It is not clear from the current studies if these results can be expanded to patients with symptomatic disease of the CNS who may likely have increased alpha amplitude. Although higher levels of CD4þ lymphocytes relate to better prognosis for HIV patients, there may be several immunologic roles for such cells. Symptomatic improvements suggest clinical benefit, but the results of these preliminary studies need replication before broader application.
At the time of the study in 1992, Highly Active Antiretroviral Therapy was not widely available to patients suffering from HIV. Therefore, compliance by afflicted individuals was easily attainable as there were very few alternative options. In a way, this contributed to the power of the study because there were fewer confounding factors that could have had a role in the parameters being tested in the study. However, this means that the study may be a bit dated in both the equipment and knowledge advances, which have been developed since this time.
For patients who received cranial electrotherapy, Alpha-Stim units were taken home for self-training. The accountability for daily training compliance was held entirely with the subjects themselves. Because of this, some may criticize that this accountability may not have been properly held in check. However, close surveillance was kept with the subjects through frequent use of questionnaires and phone calls. Also, the study occurred during a time at which there were no effective alternatives to HIV therapies, and thus patients were most likely diligent and compelled to commit to new treatment possibilities.
Future studies should address the efficacy of new neurofeedback protocols in treatment of HIV subjects. The current study used Oz training, which is no longer a frequently trained neurofeedback site. Currently, Pz is more commonly used among clinicians in stress management protocols such as alphatheta training (Peniston & Kulkokosky, 1991) . With our current technology, we can now further quantify the effects of neurofeedback as a therapy by the addition of a sham condition in which a patient receives false reward stimuli during his or her neurofeedback session. This can account for placebo bias that may be occurring during the in-clinic biofeedback process. With the advent of current antiretroviral solutions to HIV infection, it may now be difficult to provide conclusive evidence for the efficacy of neurofeedback by itself. This would require complications in creating control groups, as patients will be less inclined to stop HAART medications for an experimental treatment alternative because these medications are already proven to be effective. Therefore, although dated, the study that we conducted several years ago may be the strongest objective measure of the symptomatic benefits that neurofeedback and cranial electrotherapy provide.
